Development & Commercialisation of two novel vaccines Intranasal Covid-19 Vaccine and RTS, S Malaria Vaccine | India Science, Technology & Innovation

Acces sibility Controls

Development & Commercialisation of two novel vaccines Intranasal Covid-19 Vaccine and RTS, S Malaria Vaccine Startup

Focused on developing India’s first intranasal Covid-19 vaccine and RTS, S Malaria vaccine, with a state-of-the-art facility in Bhubaneswar.

Technology Development Board (TDB)

Area of Research

Medical Sciences

Focus Area

Vaccines, Healthcare

Sanction Amount

₹ ₹311.30 Cr (TDB assistance ₹100.00 Cr)

Status

completed

Research Paper

Technologies (If Any)

PhD Produced

N/A

Startup (If Any)

Patents

Filed :00

Grant :00